SITE010-0046

SITE010 (ESP) › SITE010-0046

SITE010-0046

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE010 (ESP) · Dr. Silva
consented 2025-10-31

enrolled

AEs

5

Serious

0

Dropout signal

–

Adverse events

5

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-09-26 (study day 148); relationship: not assessed

mild assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-09-25 (study day 147); relationship: not assessed

moderate assessed

Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-09-17 (study day 139); relationship: not assessed

moderate assessed

Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-09-15 (study day 137); relationship: NOT RELATED

mild assessed

Grade 1 Peripheral neuropathy — outcome: UNKNOWN; onset 2022-08-14 (study day 105); relationship: not assessed

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.